Pharmas Should Be Less Aggressive With Reverse Payments, Former FTC Counsel Advises
This article was originally published in The Pink Sheet Daily
Executive Summary
Payments to delay generic entry could be banned under pending legislation before Congress.
You may also be interested in...
Quelle Surprise! EU Investigators Raid Pharma Firms
Government officials investigate possible obstacles to competition in the drug industry, expect a preliminary report this fall.
Quelle Surprise! EU Investigators Raid Pharma Firms
Government officials investigate possible obstacles to competition in the drug industry, expect a preliminary report this fall.
FTC “Barrs” Firm From Anticompetitive Agreements
Federal Trade Commission gets rare victory in settlement with Barr over charges that cash payment delayed entry of generic Ovcon.